Clinical trials: Pregnancy Loss
Heavy Menstrual Bleeding
Delivering tAN to Reduce HMB: The LUNA Study
The LUNA study is a prospective, randomized, double-blind, sham-controlled, decentralized clinical trial in participants with heavy menstrual bleeding of no known structural cause.
- Trial name
- LUNA (NCT07326722)
- Testing
- Sparrow Link
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Spark Biomedical, Inc.
Solid Cancers, BRCA Mutation
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
The primary objective of the study is to evaluate the safety, tolerability, PK, PD, and prilimary efficacy of a PARG inhibitor DAT-2645 in patients with advanced/metastatic solid tumors harboring BRCA1/2 loss of function…
- Conditions
- Solid Cancers, BRCA Mutation, HRD Cancer, Breast Cancer
- Trial name
- NCT06614751
- Testing
- DAT-2645 tablet
- Where
- 2 sites in China
- Volunteers
- 112 people
- Sponsor
- Danatlas Pharmaceuticals Co., Ltd
Recurrent Miscarriage
Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage
The purpose of this clinical study is to demonstrate the shift from inflammatory cytokines to non-inflammatory cytokines in women suffering from habitual abortion treated with dydrogesterone (Duphaston).
- Trial name
- NCT00193674
- Testing
- Dydrogesterone
- Where
- 3 sites in Austria, Poland
- Volunteers
- 71 people
- Sponsor
- Abbott Products
Birth Defect, Spontaneous Abortions
Nplate® Pregnancy Exposure Registry
US study to estimate the prevalence at birth of major birth defects (ie, those that cause significant functional or cosmetic impairment, require surgery, or are life-limiting) in children born to mothers who have received Nplate®…
- Conditions
- Birth Defect, Spontaneous Abortions, Low Birth Weight
- Trial name
- NPER (NCT02090088)
- Testing
- Not applicable- observational study
- Volunteers
- 4 people
- Sponsor
- Amgen
Head and Neck Cancer, Cervical Cancer
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous T cells are engineered to express a T cell receptor that recognizes tumor-associated antigens presented on specific Human…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers
- Trial name
- NCT05812027
- Testing
- Tumor and HLA Profiling
- Where
- 21 sites in United States
- Volunteers
- 1,150 people
- Sponsor
- TScan Therapeutics, Inc.
Pregnancy, High Risk
Use of Dietary Supplements in Patients at Risk of Abortion Treated With Progesterone.
The trial aims to investigate the effect of supplementation with hyaluronic acid, alpha-lipoic acid, magnesium, vitamin D and vitamin B6 in progesterone-treated pregnant women with risk factors for abortion.
- Trial name
- NCT04874285
- Testing
- HA
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Lo.Li.Pharma s.r.l
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Early Pregnancy, Early Pregnancy Loss
EARLY-PREG: A Preconception Cohort Study Based on Counterfactuals to Study Maternal-Embryonic Molecular Interactions
EARLY-PREG is an open-cohort clinical study with a preconception, longitudinal, bidirectional and counterfactual design. The aim of this cohort is to investigate the proteomic signatures of maternal-embryonic communication by…
- Conditions
- Early Pregnancy, Early Pregnancy Loss, Childbirth, Healthy
- Trial name
- EARLY-PREG (NCT07358026)
- Testing
- EMBRYO EXPOSURE
- Where
- Chile
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA
Threatened Miscarriage
Non-interventional Study of Therapy for Threatened Miscarriage
Study the efficacy and safety of therapy for threatened miscarriage with medicinal products Utrogestan (micronized progesterone), 200 mg capsules (Besins Healthcare SA, Belgium), and Duphaston (Dydrogesterone), 10 mg coated…
- Trial name
- NCT03309735
- Testing
- Micronized progesterone, Dydrogesterone
- Where
- 17 sites in Russia
- Volunteers
- 1,241 people
- Sponsor
- Besins Healthcare
Abortion, Induced
Dilapan-S / Dilasoft E-Registry in Induced Abortion
International Observational E-Registry on the use of osmotic dilators DILAPAN-S® / DILASOFT® for cervical priming prior to induced abortion.
- Trial name
- DSREGISTRYIA (NCT02318212)
- Testing
- Dilapan-S
- Volunteers
- 439 people
- Sponsor
- Medicem International CR s.r.o.
Leiomyoma, Uterine Fibroids
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
The primary objective of this study is to test the hypothesis that a minimum 75% volume radiofrequency ablation of fibroids associated with menorrhagia results in reduction of menstrual bleeding.
- Conditions
- Leiomyoma, Uterine Fibroids, Menorrhagia
- Trial name
- FAST (NCT00768742)
- Testing
- VizAblate Intrauterine Ultrasound-Guided RF Ablation
- Where
- 3 sites in Canada
- Sponsor
- Gynesonics
Infertility, Miscarriage
Preimplantation Genetic Diagnosis (PGD) by Array Comparative Genome Hybridization (CGH) and Blastocyst Biopsy
This study evaluates the effect of single embryo transfer (SET) with and without array CGH for the evaluation of the complete chromosome complement of the blastocyst. Patients will be allocated at random into two groups.
- Trial name
- NCT01332643
- Testing
- Preimplantation Genetic Diagnosis
- Where
- Peru
- Volunteers
- 120 people
- Sponsor
- Reprogenetics
Infant Nutrition Disorders, Weight Loss
Feasibility and Validation of a Smart Changing Pad for Home Infant Weight Monitoring After Hospital Discharge
This pilot study evaluates the feasibility, usability, and clinical utility of the Woddle Smart Changing Pad and companion mobile application for infant monitoring following hospital or NICU discharge.
- Conditions
- Infant Nutrition Disorders, Weight Loss, Postnatal Care, Premature Birth
- Trial name
- NCT07718516
- Testing
- Woddle Smart Changing Pad
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Stan Kachnowski
Recurrent Miscarriage, Infertility
EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage
EmbryoGen and BlastGen contain the cytokine growth factor Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), which has been documented to give significant benefit to this difficult group of patients.
- Trial name
- BlastGen (NCT02305420)
- Testing
- EmbryoGen/ BlastGen media, Standard Cook sequential media
- Where
- Australia
- Volunteers
- 100 people
- Sponsor
- FertilitySA
Platinum Sensitive Relapsed Ovarian Cancer
Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations
Olaparib administered as monotherapy in the maintenance setting improves progression free survival compared to placebo in patients whose tumours carry loss of function (deleterious or suspected deleterious) somatic BRCA mutations…
- Trial name
- NCT02392676
- Testing
- OLAPARIB
- Where
- 29 sites in United States, Peru and 3 more
- Sponsor
- AstraZeneca
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
The purpose of this study is to determine which patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- ARIEL2 (NCT01891344)
- Testing
- Oral rucaparib
- Where
- 75 sites in United States, Australia and 4 more
- Volunteers
- 491 people
- Sponsor
- pharmaand GmbH
Menorrhagia, Heavy Menstrual Bleeding
Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss
The objective of this study is to evaluate the safety and effectiveness of the endometrial ablation device Librata in reducing menstrual blood loss at 12 months post-treatment when used in pre-menopausal women with menorrhagia…
- Trial name
- LEADER (NCT03725306)
- Testing
- Librata
- Volunteers
- 200 people
- Sponsor
- LiNA Medical
Von Willebrand Disease, Type 1, Heavy Menstrual Bleeding
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Patients With and Without Von Willebrand Disease
The objectives of this study are to determine if transcutaneous auricular neurostimulation (tAN) can modulate hemostasis, improve perceived quality of life, and improve pain during the menstrual cycle of von Willebrand Disease…
- Trial name
- VWD/HMB (NCT06064851)
- Testing
- Volta System
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Five Liters, Inc.
Blood Loss Massive, Trauma
QStat in Trauma and Obstetric Hemorrhage
This study will evaluate the performance of the Quantra System comprised of the Quantra Hemostasis Analyzer with the QStat Cartridge in trauma patients and obstetric patients with postpartum hemorrhage.
- Conditions
- Blood Loss Massive, Trauma, Post Partum Hemorrhage
- Trial name
- NCT04385953
- Testing
- Quantra System
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- HemoSonics LLC
Miscarriage, Recurrent
Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score
Recurrent pregnancy loss (RPL) is a clinical problem affecting 1-5% of couples of reproductive age. The contribution of thrombophilia to RPL is disputed.
- Trial name
- TiC-RPL (NCT03336463)
- Where
- 8 sites in Spain, United Kingdom
- Volunteers
- 364 people
- Sponsor
- Ferrer inCode, S.L.